Estimating the effectiveness of non-pharmaceutical interventions against COVID-19 transmission in the Netherlands

Jantien A. Backer*,[1], Don Klinkenberg [1], Fuminari Miura [1,2], Jacco Wallinga [1,3]

[1] National Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands

[2] Center for Marine Environmental Studies (CMES), Ehime University, Ehime, Japan

[3] Leiden University Medical Center, Leiden, the Netherlands

* corresponding author

Abstract

During the COVID-19 pandemic non-pharmaceutical interventions (NPIs) were taken to mitigate virus spread. Assessing their effectiveness is essential in policy support but often challenging, due to interactions between measures, the increase of immunity, variant emergence and seasonal effects. These factors make results difficult to interpret over a long period of time.

Using a mechanistic approach, we estimate the overall effectiveness of sets of NPIs in reducing transmission over time. Our approach quantifies the effectiveness by comparing the observed reproduction number, which is the number of secondary infections caused by a typical infected person, to a counterfactual reproduction number if no NPIs were taken. The counterfactual reproduction number accounts for seasonal variations in transmissibility, for emergence of more transmissible variants, and for changes in immunity in the population. The immune fraction is reconstructed from age-specific data of longitudinal serological surveys and vaccination coverage, taking immunity loss due to waning into account. We estimate the effectiveness of NPIs in the Netherlands from the start of the pandemic in March 2020 until the emergence of the Omicron variant in November 2021.

We find that the effectiveness of NPIs was high in March and April 2020 during the first pandemic wave and in January and February 2021, coinciding with the two periods with the most stringent measures. For both periods the effectiveness was estimated at approximately 50%, i.e., without any measures the reproduction number would have been twice as high as observed.

The proposed approach synthesises available epidemiological data from different sources to reconstruct the population-level immunity. With sufficient data, it can be applied not only to COVID-19 but also to other directly transmitted diseases, such as influenza. This method provides a near real-time assessment of the effectiveness of control measures when the required data are available.

Introduction

In most countries worldwide a great variety of non-pharmaceutical interventions (NPIs) were taken during the COVID-19 pandemic, ranging from hand-washing recommendations to strict stay-at-home orders. Especially before the introduction of vaccination, these measures were paramount to curb virus transmission. Understanding how effective the different sets of NPIs were, will help to be better prepared for future pandemics.

Many studies have been published on the effectiveness of NPIs [1,2] (and references therein). A natural outcome measure for assessing effectiveness is the reproduction number [3], which is the average number of secondary infections caused by one infected person. Existing studies use parametric regression analyses to estimate the effectiveness of individual measures by combining data on reproduction numbers and NPIs from different regions [4–9]. However, these methods assume that the effectiveness of each measure is time-invariant and independent of other measures. In practice, interactions between measures exist [10] and the effectiveness can vary over time, underlining that there is no constant effectiveness to a single measure.

Instead of attempting to isolate the effect of a specific measure, we focus on the overall effectiveness of sets of NPIs in different periods of the pandemic, using a mechanistic approach that takes the time-varying immunity, seasonality and variant emergence into account. To do so, we compare the observed reproduction number [11,12], estimated from incidence data, to a counterfactual reproduction number that would have been expected in the same (partially immune) population, at the same time during the pandemic, but without any interventions. Many studies take the relative reduction of the reproduction number as a measure for effectiveness [3], although almost all studies focus on the first pandemic wave [13,14]. A measure of effectiveness should also reflect uncertainty in observations while maintaining a practically meaningful precision. Such characteristics allow for a fair and interpretable comparison of the effectiveness of all NPIs in different periods of the pandemic.

The challenge in obtaining precise and well-calibrated estimates of effectiveness of measures lies in estimating the counterfactual reproduction number. This reproduction number changes in two basic ways. Firstly, the basic reproduction number can change over time because of the emergence of more transmissible variants [15] or because of seasonal effects [9,16–18], which translates directly to a change in the counterfactual reproduction number. Secondly, an increase in the number of immune persons in the population would decrease the counterfactual reproduction number, and vice versa. The immune fraction increases because of infections and vaccinations, and it decreases due to waning of infection-induced (i.e., natural) and vaccine-induced immunity.

We aimed to quantify the overall effectiveness of sets of NPIs against transmission in the Netherlands from the start of the pandemic (March 2020) until the emergence of the Omicron variant (November 2021). We estimated the growth advantage of emerging variants from genomic surveillance data [19] and used the seasonal effect estimated for the Netherlands [18]. We reconstructed the immune fraction of the population over time using age-specific data of

longitudinal serological surveys [20], test-positive cases [21,22] and vaccination coverage [23], assuming immunity waning rates from literature [24,25]. We obtained estimates of the effectiveness of NPIs against transmission during 28 periods with distinct sets of NPIs. To check the robustness of our conclusion, analyses were also performed with varying assumptions on immunity waning and seasonal effects. All data and code are published online [26].

Results

We determined the effectiveness of NPIs over time $\psi(t)$ by comparing the observed effective reproduction number $R_{\text{eff}}(t)$ to a counterfactual reproduction number $R_c(t)$:

$$\psi(t) = 1 - \frac{R_{\text{eff}}(t)}{R_c(t)}.$$

The effective reproduction number $R_{\text{eff}}(t)$ was calculated from case data or hospitalisation data [27] in the Netherlands during the epidemic and published online [11,12]. The counterfactual reproduction number $R_c(t)$ reflects the transmission potential without any NPIs, defined as the basic reproduction number $R_0(t)$ reduced by the immune fraction of the population over time $\phi(t)$:

$$R_c(t) = \big(1 - \phi(t)\big)R_0(t).$$

The basic reproduction number $R_0(t)$ and the immune fraction $\phi(t)$ over time were estimated by combining different data sources (see the following sections and Methods).

Change in basic reproduction number

The basic reproduction number $R_0(t)$ is defined as the average number of secondary infections caused by one infected person in a fully susceptible population without any interventions. The average reproduction number before 1 March 2020 R_0^{initial} was observed to be 2 [11,12]. The basic reproduction number can change over time, modified by seasonal fluctuations $\sigma(t)$ and the relative transmissibility $\theta(t)$ of circulating variants:

$$R_0(t) = R_0^{\text{initial}}\, \theta(t)\, \frac{\sigma(t)}{\sigma(t_{\text{ref}})},$$

where reference time t_{ref} is chosen at 1 March 2020 when the population was fully susceptible, before NPIs and before the emergence of more transmissible variants ($\theta(t_{\text{ref}}) = 1$). At this time the basic reproduction number is equal to the initial reproduction number R_0^{initial}.

The basic reproduction number increased due to the emergence of more transmissible variants. The relative transmissibility of variants compared to the wildtype was estimated from genomic surveillance data as 34%, 23%, 39% and 106% for the Alpha, Beta, Gamma and Delta variants, respectively (Suppl. S1), which is similar to reported pooled estimates for these variants [15]. Although the Omicron variant that emerged at the end of 2021 is also more transmissible, its growth advantage is known to be attributable to immune escape rather than an increased basic

reproduction number [28,29]. For this reason, the Omicron period is not included in the analysis.

Because of seasonal effects on the transmissibility of the virus, we adopted the estimate that the basic reproduction number in summer is 33% lower than in summer [18]. The combined effects of the initial reproduction number, variant emergence and seasonality on $R_0(t)$ are shown in Figure 1.

Figure 1: The basic reproduction number over time (1 January 2020 - 31 October 2021). The basic reproduction number (full, black line) depends on the initial reproduction number observed at the start of the pandemic, seasonal effects and emergence of more transmissible variants (broken, blue lines). At reference date 1 March 2020 the basic reproduction number is equal to the initial observed reproduction number.

Reconstructed immune fraction of the population

The counterfactual reproduction number also depends on the immune fraction of the population. This fraction increases over time due to (re-)infections and vaccinations, and decreases because of waning of immunity. As infection incidence and vaccination coverage differed by age group, we reconstructed the immune fraction in 8 age groups (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70+), and used their weighted average. The cumulative infection incidence is informed by a longitudinal serological survey in a representative sample of the Dutch population [20,30,31]. The cumulative infected fraction in each age group is tracked, counting all persons that have been infected at least once. In other words, reinfections will not increase the cumulative infected fraction. This fraction increases monotonically as fewer naive persons remain in the population (Fig. 2). The vaccination coverage starts to increase as the vaccination programme was rolled out in early 2021, starting in the older age groups as the

vaccination priority was from old to young. The older age groups also achieved higher vaccination coverages (Fig. 2).

Figure 2: Cumulative infected and vaccinated fractions by age group, and overall (1 February 2020 - 31 October 2022). The cumulative infected fraction is reconstructed from serological surveys with a 95% confidence interval. The daily number of reported test-positive cases in each age group was used to impute the fraction on the days between survey rounds. The vaccination data per week and age group was linearly interpolated to obtain the vaccinated fraction per day and age group. These data were used as input to calculate the immune fraction per day and per age group.

The cumulative infected and vaccinated fractions are not necessarily immune, as immunity can wane over time. We reconstructed the immune fraction in each age group and in the full population over time by combining the data in Figure 2 with an assumed waning rate for natural and vaccine-induced immunity (see Methods and Suppl. S2). The reconstruction separates the population in four subgroups: immune after infection, immune only by vaccination, those that lost their immunity (non-naïve susceptibles), and naïve susceptibles (Figure 3). Only the first two subgroups make up the immune fraction $\phi(t)$, needed to calculate the counterfactual reproduction number.

In the first year the population mainly consisted of naive individuals and individuals protected by infection, as natural immunity wanes slowly and infections occurred recently. In the second year individuals were protected by vaccination, but also the non-naive susceptible class arose,

because natural immunity had waned (see for instance the unvaccinated 0-9 age group) and because vaccine-induced immunity wanes faster than natural immunity.

Since the immune fraction depends on the waning rate, we evaluated three scenarios for waning rates of natural and vaccine-induced immunity that were taken from literature [24,25]. The reconstruction for the medium waning scenario is shown in Figure 3; the figures for slow and fast waning scenarios are given Suppl. S3.

Figure 3: Reconstructed immune fractions by age group (and overall) over time (1 February 2020 - 31 October 2021), assuming medium waning rates for natural and vaccine-induced immunity and a medium vaccine effectiveness. The population is stratified in a naive class that has never been infected nor vaccinated, a class immune after infection, a class immune after only vaccination and a non-naive susceptible class that lost its natural or vaccine-induced immunity.

To validate these calculations, we used the naive and non-naive susceptible classes to calculate reinfections and breakthrough infections as fractions of new infections and compared these to data. Overall, both fractions increase as the non-naive susceptible class increases compared to the naive class (Fig. 4). The fractions are largest for the fast waning scenario. The fraction of breakthrough infections increases faster than the fraction of reinfections, as vaccine-induced immunity wanes faster than natural immunity. The reconstructed fractions of reinfections and breakthrough infections show a similar time course as the data. Especially the reconstructed fraction of reinfections in the medium waning scenario matches the data, and at the end of the

study period the reconstructed fraction of breakthrough infections reaches values that were observed in the data. The reconstructed fractions of reinfections and breakthrough infections per age group are provided in Suppl. S4.

Figure 4: Fraction of new infections that are reinfections (left) or breakthrough infections (right) for the full population, assuming slow, medium or fast waning (1 February 2020 - 31 October 2021). Observations (black) are plotted for weeks where at least 50% of the test-positive cases has a known vaccination or infection status. Observed infections in partly vaccinated persons are counted for 0% (lower limit of grey area), 50% (mean) or 100% (upper limit of grey area) as breakthrough infection.

Effectiveness of non-pharmaceutical interventions against transmission

With the reconstructed immune fraction in the population and the basic reproduction number, the counterfactual reproduction number was calculated. Comparing this with the observed reproduction number gives the effectiveness of NPIs (Fig. 5). At the start of the pandemic (March 2020) without any control measures the effectiveness was 0% by definition, as the observed initial reproduction number was equal to the basic reproduction number.

During the first pandemic wave (March/April 2020) the effectiveness is estimated at around 50%, suggesting that without measures the observed reproduction number would have been twice as high. Towards the summer of 2020, the effectiveness decreased in steps, coinciding with the relaxation of measures [32]. It reaches a level of about 10%, when most leisure activities were allowed with restrictions, such as a maximum number of guests in restaurants.

In the winter of 2020/2021 a long lockdown was imposed with more stringent measures than in the first pandemic wave. The effectiveness of this set of measures is again estimated at around 50%. In this period the larger immune fraction due to infections and the first vaccinations was counteracted by the emergence of the more transmissible Alpha variant. As a result, the counterfactual reproduction number was higher than the reproduction number at the start of the pandemic.

In the beginning of July 2021, control measures were lifted on a large scale, including the reopening of night clubs. As this coincided with the emergence of the Delta variant, a large wave of infections followed, and the effectiveness dropped below 0% (namely -25% for medium waning, outside the scale of Fig. 5). This is caused by the observed effective reproduction number being higher than the counterfactual reproduction number, which suggests that more contacts were made than in the reference situation of March 2020. Possibly, the opening of night clubs and other leisure activities triggered a peak in human interactions. In the fall of 2021, a high vaccination coverage was achieved in all eligible age groups. Control measures were relatively light, with an estimated effectiveness of around 25%.

The different waning rate scenarios lead to similar estimates of effectiveness in the first year of the pandemic (Fig. 5). Without vaccination and relatively few infections, the non-naive susceptible class is negligible for all waning rates (Fig. 3). In the second year, the difference in the estimated effectiveness by waning scenario becomes larger mainly due to the large-scale vaccination roll-out (Fig. 2).

The timing of changes in effectiveness is expected to correspond with changes in the Oxford stringency index [33] (shown as colour band in Fig. 5). A positive change in the stringency index indicates that one or more measures were added or strenghtened, yielding an expected increase in effectiveness. Vice versa, a negative change indicates that one or more measures were lifted or alleviated, resulting in an expected decrease in effectiveness. Indeed, 22 out of 27 change points shown in Fig. 5 are consistent with this expectation. In 2 instances the stringency increases and the effectiveness decreases, and in 3 instances the opposite is found.

The uncertainty in the estimated effectiveness varies over time. At the start of pandemic, the uncertainty of the estimate is large because the observed reproduction number was based on reported hospitalisations during this period. It increases even further because of the low numbers of hospitalisations after the first wave, yielding a uncertainty that spans the full 0% to 100% range. From June 2020 onwards, the reproduction number was based on reported test-positive cases, leading to more precise estimates. At the end of the study period the uncertainty of the estimates stems from uncertainty in the immune fraction and waning rates.

Figure 5: Reproduction number and effectiveness of NPIs over time (20 February 2020 - 31 October 2021). A. Counterfactual reproduction numbers assuming slow, medium or fast waning and the 7-day

moving average of the effective reproduction number, based on hospitalisations (up to 13 June 2020) or test-positive cases (from 13 June 2020 onwards). B. The effectiveness of NPIs assuming slow, medium or fast waning, averaged over intervention periods with different sets of control measures (with constant stringency). As a timeline reference the Oxford Stringency Index [33] is depicted as a colour band from low stringency (blue) to high (red).

Sensitivity analyses

In the main analysis, we assumed that the reproduction number is reduced by 33% in summer compared to winter [18]. When varying the amplitude of the seasonal changes in reproduction numbers, the results during summer are greatly affected but not those in winter (Fig. 6). This is because the reference point lies on 1 March 2020, which anchors the peak of reproduction numbers in winter and only changes the decrease in summer. Without seasonality, the counterfactual reproduction number is much higher in summer which increases the estimated effectiveness, but even then the effectiveness remains lower in periods with lower stringency.

Figure 6: Effectiveness of NPIs over time (20 February 2020 - 31 October 2021) for different assumptions of seasonality. The reduction of the reproduction number in summer compared to winter is estimated to be 33% [18], 20% [16] and 42% [9,17]. For completeness also the model without any seasonal effect is shown. The effectiveness of NPIs (assuming medium waning) is averaged over intervention periods with different sets of control measures (with constant stringency). As a timeline reference the Oxford Stringency Index [33] is depicted as a colour band from low stringency (blue) to high (red).

Discussion

We estimated the overall effectiveness of NPIs against COVID-19 transmission over time in the Netherlands, by combining a range of data sources. The results reveal that NPIs reduced the reproduction number by about 50% during periods with the most stringent measures, with wide uncertainty bounds in April 2020 and narrow uncertainty bounds in March 2021. This estimate was consistent under different assumptions on seasonal effects or waning rates. The proposed method provides a way of constructing counterfactual reproduction numbers, which can be useful for monitoring the effectiveness of NPIs across different phases of an epidemic.

Compared to earlier reports on effectiveness of NPIs, we find a lower effectiveness of around 50% during the first wave than reported values around 80% [4,7]. The observed initial basic reproduction number of 2 is lower than other early point estimates ranging from 2.2 to 4.7 [34–38]. Also, the relative transmissibilities of emerging variants that we found are lower than some reported estimates [39,40]. All these differences can be explained by our use of a mean generation interval of 4 days [11,12] instead of the assumed values of 5 to 7 days in other studies [41–44], as a shorter generation interval leads to lower relative transmissibility of variants, a lower basic reproduction number, and hence a lower effectiveness. This emphasizes the importance of correctly specifying parameters for the natural history of infection within their context and using them consistently in the analysis. For instance, the mean generation interval of 4 days as used in the present study is strongly supported by transmission pair data observed in the early stage of the pandemic in the Netherlands.

The validity of our results can be further assessed by comparing the estimated effectiveness of NPIs against other observations in the Netherlands. One piece of evidence is the agreement in direction between changes in estimated effectiveness and changes in stringency index [33]. Indirect evidence is also provided by the results of contact surveys, as most NPIs aim to reduce contact rates. A contact survey that monitored the contact behaviour in the Dutch general population at regular intervals [45] showed that the periods in which participants had the lowest number of contacts coincided with the periods of the highest effectiveness found in this study. Furthermore, the reconstruction of the immune fractions that was used in the calculations of effectiveness is supported by data. We found good agreement between our results and data on fractions of reinfections and breakthrough infections among test-positive cases, validating the reconstructed immune fractions.

Compared to the first pandemic wave in March/April 2020, more NPIs and stricter NPIs were implemented during the lockdown in winter 2020/2021. However, for both periods the estimated effectiveness is around 50%, which suggests that the overall impact of the NPIs was lower during the winter 2020/2021 lockdown. This could be due to differences in behavioural responses across the population, such as over-compliance during the first lockdown (when for example non-essential shops were open but empty) or due to the possibility that other transmission settings (e.g., households) played a larger role. Another explanation could be that heterogeneity in compliance increased during the second lockdown, resulting in more interactions between non-compliers which can increase transmission at the populatin level [46].

We assess the impact of three possible sources of bias of the estimated effectiveness. First, the overall immune fraction is a population average of the immune fractions in different age groups. However, if some age groups play a larger role in transmission, for instance due to higher contact rates, such age-specific contributions to transmission should be weighted accordingly [47]. Disregarding this effect indeed overestimated the effectiveness in a simulation study with age stratification but not to a large extent [48]. Second, we assume that all susceptibles are equally susceptible and infectious (once infected), irrespective of whether they have been infected or vaccinated before, while there is evidence to the contrary [49–51]. Differential infectiousness and susceptibility depending on infection and vaccination history could be incorporated in the model, but this would lead to a more complex model structure with additional classes, requiring further data to support such assumption. There is no evidence it would lead to a systematic difference. Third, in reconstructing the immune fraction from the serosurvey data, we did not correct for differences between the vaccination status of survey participants and the general population. The vaccination coverage of the participants was higher than in the general population [20]. Because the vaccine protected them against infection, the cumulative infected fraction of participants could be lower than in the general population. Our reconstruction would yield an underestimation of the immune fraction and hence an overestimation of the effectiveness. This may however bias the results only from July 2021 onwards when a high vaccination coverage was reached in most age groups. Even though these biases can not be excluded, we believe their effect on the results would be limited.

The strength of the proposed method lies in its practical use to track and compare the effectiveness over a long time while avoiding assumptions about a constant effectiveness for each single control measure. Our mechanistic approach allows for combining various available data sources while propagating the uncertainty in observations e.g., those in the effective reproduction numbers and the serological survey data. The results show that the uncertainty is sufficiently small for meaningful interpretations of the estimated effectiveness while the outcomes are sufficiently accurate. The method can be applied to any country or region provided that data is available to reconstruct the immune fraction. With appropriate country-specific assumptions (for instance on the seasonal variation in reproduction number), this would allow for a multi-country comparison of effectiveness of measures. The same approach could also be used for other infectious diseases as long as the assumption holds that the counterfactual reproduction number scales linearly with the immune fraction of the population. This would be the case for influenza or other respiratory infections, but not for sexually transmitted infections.

In conclusion, the data-driven approach allowed us to assess the overall effectiveness of NPIs against COVID-19 transmission in the Netherlands over multiple waves of the pandemic. This type of analysis can be used for different stages of an outbreak, epidemic or pandemic. Retrospectively, the results can help to assess the balance between costs and burden of interventions and their resulting effectiveness. Prospectively, the results can guide public health policy makers in their expectations of the effectiveness of a set of NPIs. With timely estimates on the immune fraction in the population, the approach can be used to monitor effectiveness of NPIs against transmission on a near real-time basis during a pandemic.

Methods

Data

The analysis presented here is informed by data collected during the COVID-19 pandemic in the Netherlands. All data is publicly available, either as open data provided by government institutes or as additional data sets on the Github page accompanying this study [26]:

- Population size distribution [52]: the number of persons by age and sex on the first day of every month, from 1 January 2016 until 1 November 2023. The data is aggregated in eight age groups (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70+) and linearly interpolated between the first day of each month, yielding the population size for each age group at each date.

- Effective reproduction number [11,12]: case reproduction number based on COVID-19 hospitalisations (before 13 June 2020 and after 14 March 2023) or test-positive cases (from 13 June 2020 till 14 March 2023) with 95% confidence interval. The 7-day moving-average is taken to straighten out day-of-week effects.

- Test-positive case data [21,22]: 8.6 million test-positive cases that were reported by the Public Health Services from 28 February 2020 until 31 March 2023. They are aggregated by age group and date of (imputed) symptom onset.

- Genomic surveillance data [19]: weekly number of randomly sampled test-positive cases by SARS-CoV-2 variant from 30 November 2020 onwards; at the end of 2024 the data included almost 180,000 samples.

- Vaccination coverage data [23]: the vaccination coverage of finishing the primary vaccination series (i.e., after one or two vaccine doses depending on the vaccine), by week and 5-year age groups, from 10 January 2021 until 2 January 2022. The vaccination coverage is calculated for our 10-year age groups using the population distribution of 1 January 2022 and linearly interpolated for each date. The data was published online in January 2022 and is now included here as additional data set [26].

- Serological survey data [20,30,31]: the SARS-CoV-2 serological status of a representative sample of the Dutch population in 11 survey rounds from April 2020 until November 2023. Participant numbers range from 3,000 to 7,000 per survey round. The serostatus of participants is determined either by antibodies against Spike-S1 antigens in unvaccinated persons or by antibodies against Nucleoprotein antigens in vaccinated persons. The cumulative infected fraction of participants is calculated by age group and survey round with 95% uncertainty. These fractions are included here as additional data set [26], but the raw data is available upon request [53].

- Validation data [22]: For a part of the reported test-positive cases the vaccination status and the infection type (primary infection or reinfection) is known. For weeks in which at least 50% of the cases has a known vaccination status or infection type, the fractions of

breakthrough infections and reinfections are calculated to compare with model results. These fractions are included here as additional data sets [26].

- Oxford Stringency Index [33]: index between 0 and 100 indicating stringency of COVID-19 measures by country from 1 January 2020 until 31 December 2022. We use the average index per day in the Netherlands to define periods with constant measures and to compare our results visually.

Basic reproduction number

The basic reproduction number $R_0(t)$ can vary over time and consists of three parts: the initial basic reproduction number at the start of the pandemic, the seasonal effect and the relative transmissibility of circulating SARS-CoV-2 variants. Before interventions and without any immunity, the observed reproduction number is equal to the basic reproduction number $R_0(t)$. Taking the average of the observed reproduction number before the reference date t_{ref} of 1 March 2020 we find $R_0^{\text{initial}} = 2$.

Seasonal effects can increase $R_0(t)$ in winter due to meteorological conditions that are favorable for virus survival and crowding. The relation between the observed reproduction number and meteorological factors has been studied either by comparing many regions in the world, or by using observations throughout a complete year in one location. The reduction of the reproduction number in summer compared to winter was estimated at 20% in London and Paris [16], 42% in Europe [9,17], and 33% in the Netherlands [18]. Here we assume that seasonal variation $\sigma(t)$ in the reproduction number follows a sinusoid that reaches a maximum at t_{peak} on 1 February at an amplitude of α = 20%, i.e., a 33% reduction in summer compared to winter:

$$\sigma(t) = 1 + \alpha \cos\left(\frac{2\pi}{365}(t - t_{\text{peak}})\right),$$

where the date difference $(t - t_{\text{peak}})$ has a unit of days.

For SARS-CoV-2 the basic reproduction number has also increased over time due to the emergence of new, more transmissible variants. We assume that the increased transmissibility of all variants before the Omicron variant resulted completely in a higher $R_0(t)$, i.e., it was not caused by immune escape. From the genomic surveillance data we estimate the fraction $p_v(t)$ of each variant over time and their relative transmissibility θ_v, defined as the ratio of growth rates of the variant and wildtype (see Suppl S1). We calculate the relative transmissibility over time as a weighted average over the variants $\theta(t) = \sum_v \theta_v \; p_v(t)$.

The time-varying basic reproduction number $R_0(t)$ is the multiplication of the three components, yielding the equation in the main text.

Reconstruction of immune fraction

To reconstruct the immune fraction of the population over time, we determine the fractions of immunologically naive individuals, immune individuals, and individuals previously infected or

vaccinated but not immune, for all age groups 0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70+.

For the infection status, we use a nationwide serological survey that was held every 2-6 months from April 2020 onwards [30]. Because of the longitudinal study design, we can track which participants were infected at least once. These participants can have been infected multiple times, and they are not necessarily protected against infection. We use this monotonously increasing cumulative infected fraction in each age group as anchor points at the timing of the survey rounds. For our study period we use survey rounds 2, 4, 5 and 6. Rounds 1 and 3 are not used for fitting because the serological test was in development during round 1 and because round 3 followed round 2 too closely. We impute the fraction on the days between survey rounds using the weekly moving average of the reported test-positive case data in the same age group. We assume an incubation period of 5 days [54], and a period of 6 days between symptom onset and detectable serological response [55,56]. We assume an infected person is fully protected against infection for 6 weeks, after which immunity wanes exponentially.

For the vaccination status, we use data that contains the fraction of persons that finished their basic vaccination series (usually after two doses) per week and per age group [23]. This data is linearly interpolated to obtain the vaccinated fraction per day and age group. Up till the moment of finishing the vaccination series a person is assumed to be unprotected. We assume a linear increase from 50% to 100% of the maximal vaccine efficacy in 2 weeks after receiving the last vaccination, which is maintained for 4 weeks before exponential waning starts.

We assume three immunity waning scenarios. For the waning of natural immunity we assume that in the fast/medium/slow waning scenario 49.8% / 78·6% / 93.6% of infecteds are still protected 40 weeks after infection [24]. For the waning of vaccine-induced immunity, the slow waning rate is coupled with a high vaccine efficacy and the fast waning rate with a low vaccine efficacy, yielding best-case and worst-case scenarios. We assume that in the fast/medium/slow waning scenario vaccine protection decreases from 80% / 83% / 86% maximally to 53% / 62% / 69% 18 weeks after finishing the vaccination series [25]. From these data, the exponential waning rates after infection and vaccination are calculated (Tab. 1 and Fig. 7).

Each age group is subdivided in classes depending on the infection, vaccination and immune status, where we assume that vaccination is independent of the infection status. For simplicity, we assume all susceptibles within the same age group are equally susceptible, and when infected they are equally infectious. We calculate the fraction of new infections that were previously infected (reinfections) and vaccinated (breakthrough infections). These fractions for the full population are validated against reported data of the vaccination status and infection type of test-positive cases.

The observed cumulative infected fraction and the assumed waning rates need to be consistent with the true (unobserved) incidence. The reconstruction of the true incidence yields the immune fractions per age group, as explained in detail in Supplement S2.

Figure 7: Waning immunity profiles. For the waning of immunity after infection and after (finishing the full series of) vaccination, slow, medium and fast waning rates are estimated from literature [24,25].

Effectiveness calculation

The effectiveness depends on the ratio of the observed and counterfactual reproduction numbers. For both reproduction numbers the 95% confidence interval is known. Assuming they are both normally distributed (i.e., the 95% confidence intervals span 4 standard errors), we approximate the confidence interval of the effectiveness using Fieller's theorem [57].

Table 1 gives an overview of all parameter values that are obtained from data and literature.

Table 1: Overview of parameter values used in the analysis.

parameter	value	reference
initial basic reproduction number	2	observed R before 1 March 2020
peak day of seasonally varying reproduction number	1 February	
amplitude of seasonal variation in reproduction number α	20%	Klinkenberg et al., 2024
incubation period	5 days	Lauer et al., 2020
time between symptom onset and first detectable serogical response	6 days	Lou et al., 2020; Peeling et al., 2020

parameter	value	reference
time between infection and start of waning of immunity	42 days	
time between finishing vaccination series and maximum vaccine effectiveness	14 days	
time between finishing vaccination series and start of waning of immunity	42 days	
fraction of maximum vaccine effectiveness at finishing vaccination series	0.5	
maximum vaccine effectiveness	86% (slow)	Wu et al., 2023
	83% (medium)	
	80% (fast)	
waning rate of vaccine-induced immunity ω_{vac}	0.002622 /day (slow)	estimated from Wu et al., 2023
	0.003473 /day (medium)	
	0.004902 /day (fast)	
waning rate of natural immunity ω_{inf}	0.000278 /day (slow)	estimated from Stein et al., 2023
	0.001012 /day (medium)	
	0.002929 /day (fast)	

Funding

This study was funded by the Ministry of Health, Welfare and Sport (VWS) in the Netherlands. The authors of this study received funding from European Union's Horizon research and innovation programme - project ESCAPE (Grant agreement number 101095619). FM was supported by the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) to a project on Joint Usage/Research Center – Leading Academia in Marine and Environmental Pollution Research (LaMer). FM acknowledges fundings from Japan Society for the Promotion of Science (JSPS KAKENHI, 20J00793) and JST (JPMJPR23RA).

References

1.   Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet. 2020;395: 1973–1987. doi:10.1016/S0140-6736(20)31142-9

2.   Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ. 2021;375: e068302. doi:10.1136/bmj-2021-068302

3.   Lison A, Banholzer N, Sharma M, Mindermann S, Unwin HJT, Mishra S, et al. Effectiveness assessment of non-pharmaceutical interventions: Lessons learned from the COVID-19 pandemic. Lancet Public Health. 2023;8: e311–e317. doi:10.1016/S2468-2667(23)00046-4

4.   Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in europe. Nature. 2020;584: 257–261. doi:10.1038/s41586-020-2405-7

5.   Bo Y, Guo C, Lin C, Zeng Y, Li HB, Zhang Y, et al. Effectiveness of non-pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13 April 2020. Int J Infect Dis. 2021;102: 247–253. doi:10.1016/j.ijid.2020.10.066

6.   Liu Y, Morgenstern C, Kelly J, Lowe R, CMMID COVID-19 Working Group, Jit M. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Med. 2021;19: 40. doi:10.1186/s12916-020-01872-8

7.   Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, iak T, et al. Inferring the effectiveness of government interventions against COVID-19. Science. 2021;371. doi:10.1126/science.abd9338

8.   Sharma M, Mindermann S, Rogers-Smith C, Leech G, Snodin B, Ahuja J, et al. Understanding the effectiveness of government interventions against the resurgence of COVID-19 in Europe. Nat Commun. 2021;12: 5820. doi:10.1038/s41467-021-26013-4

9.   Paireau J, Charpignon M-L, Larrieu S, Calba C, Hozé N, Boëlle P-Y, et al. Impact of non-pharmaceutical interventions, weather, vaccination, and variants on COVID-19 transmission across departments in france. BMC Infect Dis. 2023;23: 190. doi:10.1186/s12879-023-08106-1

10.   Murphy C, Lim WW, Mills C, Wong JY, Chen D, Xie Y, et al. Effectiveness of social distancing measures and lockdowns for reducing transmission of COVID-19 in non-healthcare, community-based settings. Philos Trans A Math Phys Eng Sci. 2023;381: 20230132. doi:0.1098/rsta.2023.0132

11.   National Institute for Public Health and the Environment (RIVM). Covid-19 reproductiegetal (Covid-19 reproduction number). 2023. Available:

https://data.rivm.nl/meta/srv/dut/catalog.search#/metadata/ed0699d1-c9d5-4436-8517-27eb993eab6e

12.   Backer JA. Estimation of COVID-19 reproduction number. https://github.com/rivm-syso/estimation_R_COVID-19; 2024.

13.   Mishra S, Scott JA, Laydon DJ, Flaxman S, Gandy A, Mellan TA, et al. Comparing the responses of the UK, sweden and denmark to COVID-19 using counterfactual modelling. Sci Rep. 2021;11: 16342. doi:10.1038/s41598-021-95699-9

14.   Boer PT de, Miura F, Lagerweij GR, Wallinga J. Evaluating the COVID-19 responses of belgium, denmark, germany, the netherlands, sweden and the united kingdom, February-June 2020: A counterfactual modelling study. medRxiv. 2024. doi:10.1101/2024.07.05.24309992

15.   Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26. doi:10.2807/1560-7917.ES.2021.26.24.2100509

16.   Xu R, Rahmandad H, Gupta M, DiGennaro C, Ghaffarzadegan N, Amini H, et al. Weather, air pollution, and SARS-CoV-2 transmission: a global analysis. Lancet Planet Health. 2021;5: e671–e680. doi:10.1016/S2542-5196(21)00202-3

17.   Gavenčiak T, Monrad JT, Leech G, Sharma M, Mindermann S, Bhatt S, et al. Seasonal variation in SARS-CoV-2 transmission in temperate climates: A Bayesian modelling study in 143 European regions. PLoS Comput Biol. 2022;18: e1010435. doi:10.1371/journal.pcbi.1010435

18.   Klinkenberg D, Backer JA, Reusken C, Wallinga J. Seasonal variation in SARS-CoV-2 transmission in the Netherlands, 2020-2022: statistical evidence for a negative association with temperature. MedRxiv. 2024. doi:10.1101/2024.11.28.24318154

19.   National Institute for Public Health and the Environment (RIVM). Varianten van het coronavirus SARS-CoV-2 (Variants of SARS-CoV-2 corona virus). 2025. Available: https://www.rivm.nl/corona/actueel/virusvarianten

20.   Vos ERA, Hagen CCE van, Wong D, Smits G, Kuijer M, Wijmenga-Monsuur AJ, et al. SARS-CoV-2 seroprevalence trends in the Netherlands in the variant of concern era: Input for future response. Influenza Other Respi Viruses. 2024;18: e13312. doi:10.1111/irv.13312

21.   National Institute for Public Health and the Environment (RIVM). Covid-19 karakteristieken per casus landelijk (Covid-19 case characateristics nationwide). 2023. Available: https://data.rivm.nl/meta/srv/dut/catalog.search#/metadata/2c4357c8-76e4-4662-9574-1deb8a73f724

22.   Geubbels ELPE, Backer JA, Bakhshi-Raiez F, Beek RFHJ van der, Benthem BHB van, Boogaard J van den, et al. The daily updated Dutch national database on COVID-19 epidemiology, vaccination and sewage surveillance. Sci Data. 2023;10: 469. doi:10.1038/s41597-023-02232-w

23. National Institute for Public Health and the Environment (RIVM). Cijfers COVID-19 vaccinatieprogramma (Data on COVID-19 vaccination programme). 2024. Available: https://www.rivm.nl/corona/actueel/vaccinatiecijfers

24. Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401: 833–842. doi:10.1016/S0140-6736(22)02465-5

25. Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11: 439–452. doi:10.1016/S2213-2600(23)00015-2

26. Backer JA. Estimating the effectiveness of non-pharmaceutical interventions against COVID-19 transmission in the netherlands. https://github.com/rivm-syso/effectiveness_NPIs; 2025.

27. Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth rates and reproductive numbers. Proc Biol Sci. 2007;274: 599–604. doi:10.1098/rspb.2006.3754

28. Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, et al. SARS-CoV-2 omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7: 1161–1179. doi:10.1038/s41564-022-01143-7

29. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602: 657–663. doi:10.1038/s41586-021-04385-3

30. Vos ERA, Hartog G den, Schepp RM, Kaaijk P, Vliet J van, Helm K, et al. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. J Epidemiol Community Health. 2020. doi:10.1136/jech-2020-215678

31. Vos ERA, Boven M van, Hartog G den, Backer JA, Klinkenberg D, Hagen CCE van, et al. Associations Between Measures of Social Distancing and Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity: A Nationwide Population-based Study in the Netherlands. Clin Infect Dis. 2021;73: 2318–2321. doi:10.1093/cid/ciab264

32. National Institute for Public Health and the Environment (RIVM). Tijdlijn van coronamaatregelen 2020 (Timeline of corona measures 2020). 2023. Available: https://www.rivm.nl/gedragsonderzoek/tijdlijn-van-coronamaatregelen-2020

33. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5: 529–538. doi:10.1038/s41562-021-01079-8

34.   He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. J Med Virol. 2020;92: 2543–2550. doi:10.1002/jmv.26041

35.   Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet. 2020;395: 689–697. doi:10.1016/S0140-6736(20)30260-9

36.   Tian H, Liu Y, Li Y, Wu C-H, Chen B, Kraemer MUG, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in china. Science. 2020;368: 638–642. doi:10.1126/science.abb6105

37.   Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020;368: 395–400. doi:10.1126/science.aba9757

38.   Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP. Novel coronavirus 2019-nCoV (COVID-19): Early estimation of epidemiological parameters and epidemic size estimates. Philos Trans R Soc Lond B Biol Sci. 2021;376: 20200265. doi:10.1098/rstb.2020.0265

39.   Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage b.1.1.7 in England. Science. 2021;372: eabg3055. doi:10.1126/science.abg3055

40.   Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARS-CoV-2 lineage b.1.1.7 in England. Nature. 2021;593: 266–269. doi:10.1038/s41586-021-03470-x

41.   Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382: 1199–1207. doi:10.1056/NEJMoa2001316

42.   Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020;368: eabb6936. doi:10.1126/science.abb6936

43.   Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. Euro Surveill. 2020;25. doi:10.2807/1560-7917.ES.2020.25.17.2000257

44.   Challen R, Brooks-Pollock E, Tsaneva-Atanasova K, Danon L. Meta-analysis of the severe acute respiratory syndrome coronavirus 2 serial intervals and the impact of parameter uncertainty on the coronavirus disease 2019 reproduction number. Stat Methods Med Res. 2022;31: 1686–1703. doi:10.1177/09622802211065159

45.   Backer JA, Vos ERA, Hartog G den, Hagen CCE van, Melker HE de, Klis FRM van der, et al. Contact behaviour before, during and after the COVID-19 pandemic in the netherlands:

Evidence from contact surveys, 2016 to 2017 and 2020 to 2023. Eurosurveillance. 2024;29. doi:10.2807/1560-7917.ES.2024.29.43.2400143

46.   Leung KY, Wallinga J. Unintended outcomes of non-pharmaceutical interventions for pandemic control: how they may arise, and how they can be prevented. Manuscript in preparation. 2025.

47.   Wallinga J, Boven M van, Lipsitch M. Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci U S A. 2010;107: 923–928. doi:10.1073/pnas.0908491107

48.   Backer JA, Miura F, Leung KY, Klinkenberg D, Wallinga J. Methods to estimate the effectiveness of non-pharmaceutical interventions against transmission in an age-structured population: a simulation study. Manuscript in preparation. 2025.

49.   Gier B de, Andeweg S, Joosten R, Ter Schegget R, Smorenburg N, Kassteele J van de, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Euro Surveill. 2021;26. doi:10.2807/1560-7917.ES.2021.26.31.2100640

50.   Gier B de, Andeweg S, Backer JA, é SJ, Hof S van den, Melker HE de, et al. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. Euro Surveill. 2021;26. doi:10.2807/1560-7917.ES.2021.26.44.2100977

51.   Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022;28: 1491–1500. doi:10.1038/s41591-022-01816-0

52.   Statistics Netherlands. Population by sex and age (accessed August 2023). 2023. Available: https://opendata.cbs.nl/#/CBS/nl/dataset/83482NED/table?dl=98643

53.   National Institute for Public Health and the Environment (RIVM). PIENTER Corona onderzoek. 2025. Available: https://www.rivm.nl/pienter-corona-onderzoek

54.   Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172: 577–582. doi:10.7326/M20-0504

55.   Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020;56. doi:10.1183/13993003.00763-2020

56.   Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis. 2020;20: e245–e249. doi:10.1016/S1473-3099(20)30517-X

57.   Fieller EC. Some problems in interval estimation. Journal of the Royal Statistical Society Series B (Methodological). 1954;16: 175–185. Available: http://www.jstor.org/stable/2984043